CYP2D6 poor metabolizers had ~5-fold higher payload exposure and excess grade ≥3 mucositis, neutropenia, febrile neutropenia, ...

Iza-bren is a potentially first-in-class bispecific ADC designed to target both EGFR and HER3. It features high affinity for ...

ASCO 2026 insights on 177Lu-PSMA-617 in mHSPC: safety, marrow and kidney monitoring, and what long-term MDS/AML risks may ...

Dr McDonald shares promising data linking GLP-1 use to lower breast cancer risk, highlighting the need for clinical trials to ...

Abemaciclib (Verzenio) reduced the risk of progression or death by 62% compared with placebo in patients with advanced ...

Andrew L. Pecora, MD, discusses the significance of the long-term findings from the KEYNOTE-942 trial of intismeran autogene ...

ASCO 2026: PSMAddition shows 177Lu-PSMA-617 boosts rPFS across mHSPC subgroups, with steady safety and insights on PSMA PET ...

The IGNYTE continues to show promising outcomes despite negative FDA decisions.

Daniel Olson, MD, discusses the results of a phase 1 trial of brenetasfusp, a PRAME ImmTAC therapy in advanced melanoma.

A novel treatment approach combining triple-oral metronomic chemotherapy with ultra-low-dose immunotherapy (nivolumab; TMC-I ...

Dr. Rodriguez describes the current period in EGFR-positive lung cancer as one of active change in the first-line landscape: ...

The second is the combination of cutaneous toxicity (rash, paronychia) and venous thromboembolism (VTE), which requires ...